Investment Thesis
Zevra demonstrates exceptional revenue growth and maintains a fortress balance sheet with $95.6M cash and zero debt, positioning it well financially. However, a significant disconnect between reported net income ($37.9M) and operating cash flow ($6.1M) indicates earnings quality concerns, likely from non-operating gains or one-time items rather than sustainable operations.
Strengths
- Exceptional revenue growth of 350.9% YoY demonstrates strong commercial execution
- Fortress balance sheet with $95.6M cash, no debt, and 4.89x current ratio provides financial flexibility
- Zero long-term debt and positive ROE/ROA indicate efficient capital structure
Risks
- Major red flag: Net income ($37.9M) far exceeds operating cash flow ($6.1M), suggesting non-cash profits and earnings quality concerns
- Unusually high operating margin (144%) and net margin (104.6%) indicate likely one-time gains rather than sustainable profitability
- Small revenue base ($36.2M) typical of pharma companies carries regulatory, clinical trial, and competitive risks
Key Metrics to Watch
- Operating cash flow sustainability relative to net income in future periods
- Revenue growth trajectory and product pipeline contribution breakdown
- Clarification of non-operating gains and one-time items affecting profitability
Financial Metrics
Revenue
36.2M
Net Income
37.9M
EPS (Diluted)
$0.60
Free Cash Flow
6.1M
Total Assets
278.6M
Cash
95.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
144.0%
Net Margin
104.6%
ROE
18.4%
ROA
13.6%
FCF Margin
16.9%
Balance Sheet & Liquidity
Current Ratio
4.89x
Quick Ratio
4.84x
Debt/Equity
0.00x
Debt/Assets
26.1%
Interest Coverage
70.95x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T13:13:10.246513 |
Data as of: 2026-03-31 |
Powered by Claude AI